Nexthera Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Nexthera Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$1.62M	Buy	15,423 +11,971	+347%	+$1.28M	1.35%	19
2019 Q1	$432K	Buy	+3,452	New	+$429K	0.52%	24
2018 Q4	–	Sell	-4,000	Closed	-$857K	–	37
2018 Q3	$857K	Buy	+4,000	New	+$1M	0.16%	51
2018 Q2	–	Sell	-36,226	Closed	-$4.23M	–	52
2018 Q1	$4.23M	Buy	+36,226	New	+$4.47M	0.7%	32
2017 Q4	–	Sell	-28,536	Closed	-$1.28M	–	44
2017 Q3	$1.28M	Buy	+28,536	New	+$534K	0.33%	32

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nexthera Capital's MDGL Position: Q2 2019 in Review

Nexthera Capital increased its Madrigal Pharmaceuticals (MDGL) stake by 347% in Q2 2019, buying an estimated $1.28M and bringing the position to 15,423 shares worth $1.62M. The position accounts for 1.35% of the portfolio, ranked #19.

Nexthera Capital first reported a position in MDGL in Q3 2017 and has held it in 5 quarters since. The position peaked at $4.23M in Q1 2018. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

Nexthera Capital held 15,423 shares of Madrigal Pharmaceuticals worth $1.62M as of Q2 2019.
Nexthera Capital bought 11,971 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $1.28M.
Madrigal Pharmaceuticals made up 1.35% of Nexthera Capital's portfolio in Q2 2019, its #19 holding.
Nexthera Capital first reported a position in Madrigal Pharmaceuticals in Q3 2017 and has held it in 5 quarters since.
Nexthera Capital's Madrigal Pharmaceuticals position peaked at $4.23M in Q1 2018.
116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.